New EU Filings

Danicopan, from AstraZeneca, for the treatment of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.

This is a regularly updated searchable list of products that have been filed with the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) under the EU's centralized authorization procedure. The information is based on the EMA's monthly updated list of medicines under review at the agency, CHMP monthly meeting agendas, company press releases, and original research by the Pink Sheet

The EMA's latest monthly filings list, which comprised data extracted on 10 April, included marketing authorization applications (MAAs) for...

More from Product Reviews

More from Pink Sheet